The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach.
CB1954
DEPT
cancer
nitroreductase
prodrug
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
09
03
2021
revised:
25
03
2021
accepted:
26
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.
Identifiants
pubmed: 33918536
pii: pharmaceutics13040517
doi: 10.3390/pharmaceutics13040517
pmc: PMC8070144
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Life Sciences Research Network Wales
ID : N/A
Organisme : Knowledge Economy Skills Scholarship 2 fund
ID : N/A
Références
Biochem Pharmacol. 2013 Apr 15;85(8):1091-103
pubmed: 23399641
Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6
pubmed: 15566399
Mol Ther. 2009 Jul;17(7):1292-9
pubmed: 19367257
Biochem Pharmacol. 2018 Dec;158:192-200
pubmed: 30352235
Clin Cancer Res. 2001 Sep;7(9):2662-8
pubmed: 11555577
J Mol Biol. 2007 Apr 27;368(2):481-92
pubmed: 17350040
Langmuir. 2011 Dec 6;27(23):14300-7
pubmed: 22014024
Biochem Pharmacol. 2009 Jan 1;77(1):21-9
pubmed: 18840409
Br J Cancer. 2004 Mar 8;90(5):1084-92
pubmed: 14997211
Biochem Pharmacol. 1988 Dec 15;37(24):4671-7
pubmed: 3144286
Antioxid Redox Signal. 2008 Feb;10(2):179-206
pubmed: 18020963
Biosens Bioelectron. 2007 Jun 15;22(12):2869-75
pubmed: 17244521
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Ageing Res Rev. 2008 Jan;7(1):1-7
pubmed: 18162444
Biochem Pharmacol. 1992 Dec 15;44(12):2289-95
pubmed: 1472094
Biochem Pharmacol. 2015 Dec 1;98(3):392-402
pubmed: 26415543
Microbiologyopen. 2020 Oct;9(10):e1110
pubmed: 32979040
Curr Pharmacol Rep. 2016 Dec;2(6):299-308
pubmed: 28042530
J Clin Oncol. 2004 May 1;22(9):1546-52
pubmed: 15051757
Biochem J. 2015 Oct 15;471(2):131-53
pubmed: 26431849
J Funct Biomater. 2019 Oct 01;10(4):
pubmed: 31581475
Int J Cancer. 2000 Jun 15;86(6):848-54
pubmed: 10842200
Biochem Pharmacol. 1991 Oct 9;42(9):1691-7
pubmed: 1930294
Gene Ther. 1998 Aug;5(8):1061-9
pubmed: 10326029
Biochem Pharmacol. 2010 Mar 1;79(5):678-87
pubmed: 19852945
J Biol Chem. 1991 Mar 5;266(7):4119-25
pubmed: 1999405
ChemMedChem. 2008 Jan;3(1):20-53
pubmed: 17963208
Nature. 1958 Aug 16;182(4633):421-2
pubmed: 13577867
Eur J Med Chem. 2001 Jul-Aug;36(7-8):577-95
pubmed: 11600229
Br J Cancer. 2009 Jun 16;100(12):1903-11
pubmed: 19455141
J Biotechnol. 2010 Oct 1;150(1):190-4
pubmed: 20727918
J Biol Chem. 1991 Mar 5;266(7):4126-30
pubmed: 1999406
Biodegradation. 2011 Apr;22(2):463-74
pubmed: 20862523
Eur J Pharm Sci. 2019 Jan 15;127:217-224
pubmed: 30414836
Anal Chem. 2007 Jun 1;79(11):4215-21
pubmed: 17458937
Can J Microbiol. 1981 Jan;27(1):81-6
pubmed: 7011517
J Biomed Biotechnol. 2003;2003(1):48-70
pubmed: 12686722